. 2020 Feb 5;156(4):384–392. doi: 10.1001/jamadermatol.2019.4835

Table 3. Psoriasis Severity Through 6-Month Follow-up by Treatment Group for PGA and PASI.

Treatment	PGA 0/1^a^,^b^,^c		PASI75^a^,^b^,^c		PGA Score^a^,^b^,^d		PASI Score^a^,^b^,^d
Treatment	No. of Patients	OR (CI)	No. of Patients	OR (CI)	No. of Patients	Effect (SD)	No. of Patients	Effect (SD)
Methotrexate	135	1 [Reference]	36	1 [Reference]	135	0 [Reference]	36	0 [Reference]
Biologic	42^e	2.00 (0.98 to 4.00)	34^f	4.56 (2.02 to 10.27)	42^e	−0.31 (−0.56 to −0.06)	34^f	−3.13 (−4.33 to −1.94)
P Value		.06		<.001		.02		<.001

Abbreviations: PASI, Psoriasis Area and Severity Index; PASI75, 75% or greater improvement in PASI; PGA, Physician Global Assessment.

^{^a}

Methotrexate treatment could have been preceded by other conventional systemics or biologic agents. Treatment with biologics could have been preceded by conventional systemics (including methotrexate) or other biologic agents. However, patients were treated at any one time with a single systemic medication.

^{^b}

Participating sites provided PASI and/or PGA scores at medication initiation and during at least 1 follow-up visit. Patient numbers are therefore not identical in both groups. The percentage of missing data was less than 10% at each time point.

^{^c}

The association between medication and severity scores during follow-up was studied by general estimating equation modeling. Patients who received methotrexate and biologics at different times were included in both treatment groups. Sex, age at treatment start, and disease duration did not influence the results and were therefore not included in the model. Follow-up (months) and psoriasis severity scores at the start of treatment also had an association with psoriasis severity at some point during 6-month follow-up (eTables 3 and 4 in the Supplement). There was no interaction between follow-up duration and medication. Severity score at the start of treatment refers to the corresponding PASI and/or PGA score at medication initiation.

^{^d}

Etanercept was the most frequently prescribed biologic (29 [69.0%]) followed by adalimumab (10 [23.8%]), ustekinumab (2 [4.8%]), and infliximab (1 [2.4%]).

^{^e}

Etanercept was the most frequently prescribed biologic (25 [73.5%]) followed by adalimumab (5 [14.7%]) and ustekinumab (4 [11.8%]).

^{^f}

The association between medication and severity scores during follow-up was studied by linear mixed modeling. Patients who received methotrexate and biologics at different times were included in both treatment groups. Sex, age at treatment start, and disease duration did not influence the results and were therefore not included in the model. Follow-up (months) and psoriasis severity scores at the start of treatment also had an association with psoriasis severity through the 6-month follow-up period (eTable 4 in the Supplement). There was no interaction between follow-up duration and medication.